Necrotizing Enterocolitis Market

Market Overview:

The 7 major necrotizing enterocolitis markets reached a value of US$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.

The necrotizing enterocolitis market has been comprehensively analyzed in IMARC's new report titled "Necrotizing Enterocolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Necrotizing enterocolitis refers to a serious medical condition that primarily affects premature infants, especially those born before 32 weeks of gestation. It is characterized by inflammation and tissue death in the intestine, particularly in the colon and small intestine. The indications associated with this condition can vary in severity but often include feeding intolerance, abdominal distension, blood in the stool, lethargy, etc. In some cases, infants suffering from the ailment may exhibit signs of sepsis, such as a high temperature or an unstable heart rate. The diagnosis of necrotizing enterocolitis mainly involves a combination of clinical evaluation, laboratory tests, and imaging studies. The healthcare provider may also utilize abdominal scans to identify signs of intestinal damage or pneumatosis, which is the presence of gas in the intestinal wall. Additionally, blood tests might be conducted to aid in assessing the patient’s overall health and detecting indications of infection or organ dysfunction.

The increasing cases of premature births, which make infants prone to inflammation and infection due to immature gastrointestinal systems, are primarily driving the necrotizing enterocolitis market. In addition to this, the inflating utilization of effective treatments, such as antibiotics and intravenous fluids, to manage the ailment and prevent further complications is creating a positive outlook for the market. These therapies help to combat infections as well as maintain hydration and electrolyte balance in patients. Moreover, the widespread adoption of specialized feeding strategies, including parenteral nutrition and the slow advancement of enteral feeds, which can reduce the risk of disease development, is further bolstering the market growth. Apart from this, the rising usage of advanced medical technologies, such as imaging techniques like X-rays and ultrasound, since they aid in the accurate diagnosis of necrotizing enterocolitis cases, is acting as another significant growth-inducing factor. Additionally, the escalating implementation of preventive measures, including strict hygiene protocols and careful monitoring of high-risk neonates in neonatal intensive care units to curb the incidence of illness, is also augmenting the market growth. Furthermore, the rising R&D activities in the fields of regenerative drugs and stem cell therapies, which offer promising potential for improved treatment outcomes, are expected to drive the necrotizing enterocolitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the necrotizing enterocolitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for necrotizing enterocolitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the necrotizing enterocolitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the necrotizing enterocolitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the necrotizing enterocolitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current necrotizing enterocolitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the necrotizing enterocolitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the necrotizing enterocolitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the necrotizing enterocolitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with necrotizing enterocolitis across the seven major markets?
• What is the size of the necrotizing enterocolitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of necrotizing enterocolitis?
• What will be the growth rate of patients across the seven major markets?
   

Necrotizing Enterocolitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for necrotizing enterocolitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the necrotizing enterocolitis market?
• What are the key regulatory events related to the necrotizing enterocolitis market?
• What is the structure of clinical trial landscape by status related to the necrotizing enterocolitis market?
• What is the structure of clinical trial landscape by phase related to the necrotizing enterocolitis market?
• What is the structure of clinical trial landscape by route of administration related to the necrotizing enterocolitis market?